AN2 Therapeutics, Inc.(ANTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ANTX AN2 Therapeutics, Inc.

未开盘 06-05 16:00:00 EDT

3.82

-0.35

-8.39%

盘后3.75

-0.07-1.83%

16:27 EDT

最高4.19	最低3.75	成交量17.82万
今开4.19	昨收4.17	日振幅10.55%
总市值1.37亿	流通市值4,108万	总股本3,594万
成交额69.36万	换手率1.66%	流通股本1,076万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ANTX","market":"US","secType":"STK","nameCN":"AN2 Therapeutics, Inc.","latestPrice":3.82,"timestamp":1780689600000,"preClose":4.17,"halted":0,"volume":178156,"hourTrading":{"tag":"盘后","latestPrice":3.75,"preClose":3.82,"latestTime":"16:27 EDT","volume":627,"amount":2351.6,"timestamp":1780691247075,"change":-0.07,"changeRate":-0.018325,"amplitude":0.018325},"delay":0,"changeRate":-0.0839328537170264,"floatShares":10755200,"shares":35941195,"eps":-1.106854,"marketStatus":"未开盘","change":-0.35,"latestTime":"06-05 16:00:00 EDT","open":4.19,"high":4.19,"low":3.75,"amount":693586,"amplitude":0.105516,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.106854,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1780905600000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1648180800000,"exchange":"NASDAQ","adjPreClose":4.17,"preHourTrading":{"tag":"盘前","latestPrice":4.22,"preClose":4.17,"latestTime":"08:55 EDT","volume":1015,"amount":4283.3,"timestamp":1780664140055,"change":0.05,"changeRate":0.01199,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":3.75,"preClose":3.82,"latestTime":"16:27 EDT","volume":627,"amount":2351.6,"timestamp":1780691247075,"change":-0.07,"changeRate":-0.018325,"amplitude":0.018325},"volumeRatio":0.9797328881101883},"requestUrl":"/m/hq/s/ANTX","defaultTab":"news","newsList":[{"id":"1189726619","title":"AN2 Therapeutics公布支持口服AN2-502998进入慢性恰加斯病二期研究的积极辅助数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1189726619","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189726619?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:02","pubTimestamp":1780570979,"startTime":"0","endTime":"0","summary":"AN2 Therapeutics公司宣布了支持其口服候选药物AN2-502998推进至慢性恰加斯病二期临床研究的关键辅助数据。该数据结果积极，为后续的临床开发提供了有力依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161456400","title":"AN2 Therapeutics 一期临床试验显示AN2-502998安全性良好且无剂量限制性毒性","url":"https://stock-news.laohu8.com/highlight/detail?id=1161456400","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161456400?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:02","pubTimestamp":1780570977,"startTime":"0","endTime":"0","summary":"AN2 Therapeutics公司公布，其候选药物AN2-502998的一期临床研究取得了积极结果。数据显示，该药物展现出良好的安全性特征，并且在试验中未观察到剂量限制性毒性。这一进展为后续的临床开发计划奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181946041","title":"Leerink Partners将AN2 Therapeutics评级上调至“跑赢大盘”，目标价大幅调升至9美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1181946041","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181946041?lang=zh_cn&edition=full","pubTime":"2026-05-14 18:07","pubTimestamp":1778753234,"startTime":"0","endTime":"0","summary":"投资机构Leerink Partners宣布，将生物制药公司AN2 Therapeutics, Inc.的股票评级从“与大盘持平”上调至“跑赢大盘”。与此同时，该机构将其目标股价进行了显著上调，从原先的1美元大幅提升至9美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112613166","title":"AN2 Therapeutics公司与杰富瑞集团签署公开市场销售协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1112613166","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112613166?lang=zh_cn&edition=full","pubTime":"2026-04-21 04:36","pubTimestamp":1776717374,"startTime":"0","endTime":"0","summary":"AN2 Therapeutics公司已与杰富瑞集团达成一项公开市场销售协议。该协议签署日期为2026年4月9日，相关文件已正式提交美国证券交易委员会备案。此类融资安排通常用于上市公司灵活筹集资金，同时最大限度减少对股价的直接冲击。此次协议的签署标志着AN2 Therapeutics公司正积极拓展融资渠道，为后续业务发展提供资金支持。生物制药企业的研发周期长、资金需求大，通过资本市场操作获取资金是其维持研发投入的重要方式。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198433007","title":"AN2 Therapeutics公司与杰富瑞集团达成协议 拟增发普通股募资最高8000万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1198433007","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198433007?lang=zh_cn&edition=full","pubTime":"2026-04-10 05:24","pubTimestamp":1775769853,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会最新披露的文件显示，生物制药企业AN2 Therapeutics公司已与知名投行杰富瑞集团签署股权分销协议，获得通过公开发行普通股募集最高8000万美元资金的资格。\n该协议允许AN2 Therapeutics公司在市场条件适宜时，分批向公众投资者出售公司普通股。此次融资安排将为公司核心药物研发项目提供战略资金支持，同时增强企业现金流弹性。\n值得注意的是，此类股权分销协议通常赋予发行方在约定期限内灵活选择发行时机和规模的权力，使企业能够根据市场波动适时优化融资结构。此次8000万美元的融资额度将受限于实际市场认购情况与协议条款约束。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190327144","title":"AN2 Therapeutics与Jefferies签署8000万美元普通股公开市场销售协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1190327144","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190327144?lang=zh_cn&edition=full","pubTime":"2026-04-10 05:06","pubTimestamp":1775768772,"startTime":"0","endTime":"0","summary":"AN2 Therapeutics公司近日向美国证券交易委员会提交文件，宣布与投资银行Jefferies签订公开市场销售协议。根据协议条款，公司可通过Jefferies在公开市场发行普通股，募集资金总额最高达8000万美元。\n该融资安排将为AN2 Therapeutics提供灵活的资金渠道，支持其临床阶段生物制药业务的持续推进。通过公开市场销售普通股的方式，公司可根据市场情况适时进行融资，优化资金使用效率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109135817","title":"AN2 Therapeutics启动Epetraborole治疗脓肿分枝杆菌复合体肺病的2期研究者发起临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1109135817","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109135817?lang=zh_cn&edition=full","pubTime":"2026-03-31 19:01","pubTimestamp":1774954876,"startTime":"0","endTime":"0","summary":"AN2 Therapeutics, Inc.宣布，正式启动针对脓肿分枝杆菌复合体肺病的2期研究者发起临床试验，该试验将评估其在研药物Epetraborole的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108950101","title":"AN2 Therapeutics公布2025年第四季度及全年财务业绩，并披露近期业务与科研进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1108950101","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108950101?lang=zh_cn&edition=full","pubTime":"2026-03-18 04:01","pubTimestamp":1773777707,"startTime":"0","endTime":"0","summary":"AN2 Therapeutics, Inc.（简称AN2 Therapeutics）近日正式发布了其2025年第四季度及全年的财务报告，同时概述了公司在业务拓展与科学研究方面取得的最新成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176259340","title":"AN2 Therapeutics, Inc. 二期临床试验预计2026年第三季度启动，数据读出最早将于2026年第四季度开始并贯穿2027年全年","url":"https://stock-news.laohu8.com/highlight/detail?id=1176259340","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176259340?lang=zh_cn&edition=full","pubTime":"2026-03-04 05:01","pubTimestamp":1772571673,"startTime":"0","endTime":"0","summary":"AN2 Therapeutics, Inc. 宣布其关键研发项目取得重要进展。公司计划于2026年第三季度正式启动二期临床试验，标志着该疗法开发进入新的阶段。\n根据规划，该项研究的首批数据读出时间点预计最早为2026年第四季度。此后，整个2027年将持续有新的临床数据陆续公布，为评估疗法的安全性和有效性提供关键依据。\n这一时间表的公布，为关注该公司研发进展的投资者和市场观察人士提供了明确预期。后续数据读出节奏将贯穿2027年全年，形成持续的数据流。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158774485","title":"AN2 Therapeutics计划将口服Epetraborole推进至真性红细胞增多症二期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1158774485","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158774485?lang=zh_cn&edition=full","pubTime":"2026-03-04 05:00","pubTimestamp":1772571611,"startTime":"0","endTime":"0","summary":"AN2 Therapeutics, Inc.宣布，公司计划将口服药物Epetraborole推进至针对真性红细胞增多症(PV)的二期临床研究阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194179960","title":"AN2 Therapeutics获FDA批准开展Epetraborole针对脓肿分枝杆菌肺病90人研究者启动试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1194179960","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194179960?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:02","pubTimestamp":1768219347,"startTime":"0","endTime":"0","summary":"AN2 Therapeutics, Inc.宣布，其药品Epetraborole用于治疗脓肿分枝杆菌肺病的90人规模研究者启动试验（IIT）已获得美国食品药品监督管理局（FDA）的批准，可继续进行。\n该试验将由研究者主导，旨在评估Epetraborole在特定患者群体中的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514016181","title":"Citizens Capital Markets：重申AN2 Therapeutics(ANTX.US)评级，由优于大市调整至优于大市评级, 目标价由5.00美元调整至5.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514016181","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514016181?lang=zh_cn&edition=full","pubTime":"2025-02-25 23:41","pubTimestamp":1740498087,"startTime":"0","endTime":"0","summary":"Citizens Capital Markets：重申AN2 Therapeutics(ANTX.US)评级，由优于大市调整至优于大市评级, 目标价由5.00美元调整至5.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25234148384500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","ANTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2490633608","title":"An2 Therapeutics, Inc.盘中异动 急速拉升5.30%报1.59美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490633608","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490633608?lang=zh_cn&edition=full","pubTime":"2024-12-11 22:36","pubTimestamp":1733927805,"startTime":"0","endTime":"0","summary":"北京时间2024年12月11日22时36分，An2 Therapeutics, Inc.股票出现异动，股价大幅拉升5.30%。截至发稿，该股报1.59美元/股，成交量5.2028万股，换手率0.17%，振幅2.65%。An2 Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.01%。An2 Therapeutics, Inc.公司简介：AN2 Therapeutics Inc是一家临床阶段的生物制药公司，开发治疗罕见、慢性和严重传染病的药物，这些疾病的需求未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121122364695e8f857&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121122364695e8f857&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","ANTX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2490011590","title":"An2 Therapeutics, Inc.盘中异动 早盘急速上涨5.63%报1.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490011590","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490011590?lang=zh_cn&edition=full","pubTime":"2024-12-10 22:35","pubTimestamp":1733841334,"startTime":"0","endTime":"0","summary":"北京时间2024年12月10日22时35分，An2 Therapeutics, Inc.股票出现异动，股价快速上涨5.63%。截至发稿，该股报1.50美元/股，成交量7061股，换手率0.02%，振幅4.23%。An2 Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.17%。An2 Therapeutics, Inc.公司简介：AN2 Therapeutics Inc是一家临床阶段的生物制药公司，开发治疗罕见、慢性和严重传染病的药物，这些疾病的需求未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223534984b0c1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223534984b0c1d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","ANTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2488924925","title":"An2 Therapeutics, Inc.盘中异动 下午盘股价大跌5.00%报1.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488924925","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488924925?lang=zh_cn&edition=full","pubTime":"2024-12-04 02:21","pubTimestamp":1733250109,"startTime":"0","endTime":"0","summary":"北京时间2024年12月04日02时21分，An2 Therapeutics, Inc.股票出现波动，股价快速跳水5.00%。截至发稿，该股报1.52美元/股，成交量8.9225万股，换手率0.30%，振幅4.38%。An2 Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.64%。An2 Therapeutics, Inc.公司简介：AN2 Therapeutics Inc是一家临床阶段的生物制药公司，开发治疗罕见、慢性和严重传染病的药物，这些疾病的需求未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120402214998e52592&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120402214998e52592&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","BK4007","ANTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2488729966","title":"An2 Therapeutics, Inc.盘中异动 急速下挫5.99%报1.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488729966","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488729966?lang=zh_cn&edition=full","pubTime":"2024-12-02 22:33","pubTimestamp":1733150032,"startTime":"0","endTime":"0","summary":"北京时间2024年12月02日22时33分，An2 Therapeutics, Inc.股票出现异动，股价快速跳水5.99%。An2 Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Senti Biosciences, Inc.、Purple Biotech Ltd、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大，Senti Biosciences, Inc.、Purple Biotech Ltd、Revelation Biosciences, Inc.较为活跃，换手率分别为724.43%、690.02%、204.07%，振幅较大的相关个股有Senti Biosciences, Inc.、Purple Biotech Ltd、Renovaro Inc.，振幅分别为49.54%、20.27%、17.49%。An2 Therapeutics, Inc.公司简介：AN2 Therapeutics Inc是一家临床阶段的生物制药公司，开发治疗罕见、慢性和严重传染病的药物，这些疾病的需求未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202223352971b2e16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202223352971b2e16&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","ANTX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2487954550","title":"An2 Therapeutics, Inc.盘中异动 股价大涨8.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2487954550","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487954550?lang=zh_cn&edition=full","pubTime":"2024-11-29 22:30","pubTimestamp":1732890623,"startTime":"0","endTime":"0","summary":"北京时间2024年11月29日22时30分，An2 Therapeutics, Inc.股票出现异动，股价急速拉升8.03%。An2 Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Cabaletta Bio, Inc.、Passage Bio, Inc.、Pyxis Oncology, Inc.涨幅较大，Silo Pharma, Inc.、Tc Biopharm  Plc、Applied Therapeutics, Inc.较为活跃，换手率分别为133.69%、11.55%、7.12%，振幅较大的相关个股有Os Therapies Incorporated、Cero Therapeutics Holdings, Inc.、Gyre Therapeutics, Inc.，振幅分别为6.31%、5.44%、2.46%。An2 Therapeutics, Inc.公司简介：AN2 Therapeutics Inc是一家临床阶段的生物制药公司，开发治疗罕见、慢性和严重传染病的药物，这些疾病的需求未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129223023971aa629&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129223023971aa629&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ANTX","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2486284080","title":"An2 Therapeutics, Inc.盘中异动 股价大涨5.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486284080","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486284080?lang=zh_cn&edition=full","pubTime":"2024-11-25 22:37","pubTimestamp":1732545454,"startTime":"0","endTime":"0","summary":"北京时间2024年11月25日22时37分，An2 Therapeutics, Inc.股票出现异动，股价大幅上涨5.97%。An2 Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.36%。An2 Therapeutics, Inc.公司简介：AN2 Therapeutics Inc是一家临床阶段的生物制药公司，开发治疗罕见、慢性和严重传染病的药物，这些疾病的需求未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125223734971a85e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125223734971a85e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4007","ANTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2485932552","title":"An2 Therapeutics, Inc.2024财年第三财季实现净利润-12.75百万美元，同比增加23.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485932552","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485932552?lang=zh_cn&edition=full","pubTime":"2024-11-23 00:00","pubTimestamp":1732291249,"startTime":"0","endTime":"0","summary":"11月23日，An2 Therapeutics, Inc.公布财报，公告显示公司2024财年第三财季净利润为-12.75百万美元，同比增加23.70%；其中营业收入为0.00美元，每股基本收益为-0.43美元。机构评级：截至2024年11月23日，当前有3家机构对An2 Therapeutics, Inc.目标价做出预测，其中目标均价为2.67美元，其中最低目标价为1.00美元，最高目标价为5.00美元。公司简介：AN2 Therapeutics Inc是一家临床阶段的生物制药公司，开发治疗罕见、慢性和严重传染病的药物，这些疾病的需求未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000102a24e4863&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000102a24e4863&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","ANTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2485261379","title":"An2 Therapeutics, Inc.盘中异动 快速上涨5.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485261379","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485261379?lang=zh_cn&edition=full","pubTime":"2024-11-22 22:31","pubTimestamp":1732285874,"startTime":"0","endTime":"0","summary":"北京时间2024年11月22日22时31分，An2 Therapeutics, Inc.股票出现异动，股价急速拉升5.37%。An2 Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.37%。其相关个股中，Virpax Pharmaceuticals, Inc.、Exicure, Inc.、Replimune Group, Inc.涨幅较大，Virpax Pharmaceuticals, Inc.、Molecular Templates, Inc.、Exicure, Inc.较为活跃，换手率分别为499.28%、61.77%、35.49%，振幅较大的相关个股有Exicure, Inc.、Virpax Pharmaceuticals, Inc.、Kairos Pharma, Ltd.，振幅分别为10.96%、9.21%、9.19%。An2 Therapeutics, Inc.公司简介：AN2 Therapeutics Inc是一家临床阶段的生物制药公司，开发治疗罕见、慢性和严重传染病的药物，这些疾病的需求未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122223114abd7918d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122223114abd7918d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","ANTX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.an2therapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1178},{"period":"1month","weight":-0.1785},{"period":"3month","weight":0.3404},{"period":"6month","weight":2.4727},{"period":"1year","weight":2.4414},{"period":"ytd","weight":2.3509}],"compareEarnings":[{"period":"1week","weight":-0.025},{"period":"1month","weight":0.0051},{"period":"3month","weight":0.0969},{"period":"6month","weight":0.0756},{"period":"1year","weight":0.2437},{"period":"ytd","weight":0.0816}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"AN2 Therapeutics, Inc.于2017年2月24日在特拉华州注册成立，并于2019年11月开始运营。该公司是一家临床阶段的生物制药公司，专注于利用其硼化学平台发现和开发新型小分子疗法。其研发管线针对血液疾病、感染性疾病和肿瘤学领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":0.008802},{"month":2,"riseRate":0,"avgChangeRate":-0.236128},{"month":3,"riseRate":0.75,"avgChangeRate":0.566919},{"month":4,"riseRate":0.4,"avgChangeRate":-0.037373},{"month":5,"riseRate":0,"avgChangeRate":-0.138001},{"month":6,"riseRate":0.4,"avgChangeRate":-0.001113},{"month":7,"riseRate":0.5,"avgChangeRate":0.061464},{"month":8,"riseRate":0.75,"avgChangeRate":0.333856},{"month":9,"riseRate":0.75,"avgChangeRate":0.04615},{"month":10,"riseRate":0.25,"avgChangeRate":-0.073924},{"month":11,"riseRate":0.5,"avgChangeRate":0.085581},{"month":12,"riseRate":0.5,"avgChangeRate":-0.00143}],"exchange":"NASDAQ","name":"AN2 Therapeutics, Inc.","nameEN":"AN2 Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AN2 Therapeutics, Inc.(ANTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供AN2 Therapeutics, Inc.(ANTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"AN2 Therapeutics, Inc.,ANTX,AN2 Therapeutics, Inc.股票,AN2 Therapeutics, Inc.股票老虎,AN2 Therapeutics, Inc.股票老虎国际,AN2 Therapeutics, Inc.行情,AN2 Therapeutics, Inc.股票行情,AN2 Therapeutics, Inc.股价,AN2 Therapeutics, Inc.股市,AN2 Therapeutics, Inc.股票价格,AN2 Therapeutics, Inc.股票交易,AN2 Therapeutics, Inc.股票购买,AN2 Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AN2 Therapeutics, Inc.(ANTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供AN2 Therapeutics, Inc.(ANTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}